CoChat

Visceral adipose tissue visfatin in nonalcoholic fatty liver disease

Open access
Gaddipati, Radhika, Mitnala, Sasikala, Padaki, Nagarajarao, Mukherjee, Rathindra Mohan, Sekaran, Anuradha, Jayaraj-Mansard, Magnus, Rabella, Pradeep, Rao-Guduru, Venkat, Reddy-Duwuru, Nageshwar · 2010 · Annals of Hepatology
Cited by 39

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Visfatin is a novel adipocytokine predominantly expressed and secreted by visceral adipose tissue. It is realized for its multiple functions of central importance in NAD biosynthesis, innate immunity and inflammation. Its phosphoribosyl transferase activity regulates cellular energetics and NAD dependent enzymes such as SIRTUINS. Although its expression in various tissues and circulating levels are documented, visceral visfatin levels in Nonalcoholic fatty liver disease (NAFLD) patients have not been reported. OBJECTIVE: The aim of the present study was to assess visceral adipose tissue visfatin levels in NAFLD. Materials and methods. A total of 115 patients undergoing diagnostic laparoscopy were recruited in the study and categorized into two groups based on standard criteria for NAFLD. Visceral adipose tissue TNF-a, IL-6 and visfatin levels were measured by ELISA. Blood glucose, lipids, liver enzymes and non esterified fatty acids (NEFA) were estimated using standard procedures. Formalin fixed, Hematoxylene Eosin stained liver biopsy specimens were examined for the presence of steatosis and the degree of steatosis was ascertained as per Brunt.s classification. RESULTS: The visceral visfatin level declined significantly (P < 0.001) in all groups of NAFLD as compared to non NAFLD group, while plasma NEFA level increased with progressive steatosis (P < 0.02). Significant increase in TNF a was observed in all groups of NAFLD, while IL-6 increased in NASH only. CONCLUSION: A significant decline in visceral adipose tissue visfatin level was found to be associated with degree of steatosis in NAFLD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1665-2681(19)31635-7

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 39

Metadata

Authors
Gaddipati, R., Mitnala, S., Padaki, N., Mukherjee, R. M., Sekaran, A., Jayaraj-Mansard, M., Rabella, P., Rao-Guduru, V., & Reddy-Duwuru, N.
Venue
Annals of Hepatology
Publisher
Elsevier BV
Published
2010-07
Volume
9
Issue
3
Pages
266-270
ISSN
1665-2681 (ISSN-L)
OpenAlex
W2409602175
Cited by
39
References
2
FWCI
1.47
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1016/s1665-2681(19)31635-7
The paper
Gaddipati, R., Mitnala, S., Padaki, N., Mukherjee, R. M., Sekaran, A., Jayaraj-Mansard, M., Rabella, P., Rao-Guduru, V., & Reddy-Duwuru, N. (2010). Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Annals of Hepatology. https://doi.org/10.1016/s1665-2681(19)31635-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.